Tranzyme Pharma Inc.

Socpra Sciences Et Genie S.e.c.

Socpra Sciences Sante Et Humaines S.e.c.

Ocera Therapeutics, Inc.

Éric Marsault

Hamid R Hoveyda

Mark L Peterson

Sylvie Beaubien

Luc Ouellet

Kamel Benakli

Graeme Lovat Fraser

Mahesh Ramaseshan

Yves Dory

Pierre Deslongchamps

Gérald Villeneuve

Daniel Fortin

François Malouin

Sophie Beauchemin

Carl St-Louis

Simon Boulanger

Isabelle Guay

Félix Chagnon

Ruoxi Lan

Helmut Thomas

Philippe Sarret

Richard Leduc

Martin Richter

Zhigang Wang

Marc Sousbie

Jean-Michel Longpré

Shigui Li

Robert Dèziel

Martin Vezina

Élie Besserer-Offroy

Rebecca Brouillette

Michael Desgagné

Martin Brassard

Magali Chartier

Michael Desgagne

Éloïc Colombo

Hamid Hoveyda

David Drutz

Alain Rouillard

The present disclosure provides a macrocyclic compound of formula (I) (I), compositions and kits comprising this compound and their use for preventing or treating pain without inducing hypothermia, hypotension or ileum relaxation.

Neurotensinergic agonists and methods of using same preventing or treating pain

The present invention provides a macrocyclic compound of formula (I)  compositions and kits comprising this compound and their use for preventing or treating pain, or inducing hypothermia or hypotension.

Macrocyclic compounds and methods of preventing or treating pain

The present invention provides bacterial ATP synthase inhibitors such as a compound of formula (I): There are provided compositions and kits using such compounds and inhibitors.

Steroid alkaloids and compositions and kits thereof

The present invention provides bacterial ATP synthase inhibitors such as a compound of formula (I): (Formula (I)) (A) in combination with an aminoglycoside antibiotic for preventing or treating a bacterial infection in a subject; or (B) (a) for preventing or treating an infection caused by an electron transport-deficient bacteria in a subject; or (b) for the disinfection, sterilization and/or antisepsis of an object contaminated with an electron transport-deficient bacteria. There are provided compositions and kits using such compounds and inhibitors. 

ATP synthase inhibitors and steroid alkaloids and uses thereof as antimicrobial agents and as potentiators for aminoglycosides against pathogenic bacteria

Novel spatially-defined macrocyclic compounds incorporating peptide bond surrogates are disclosed. Libraries of these macrocycles are then used to select one or more macrocycle species that exhibit a specific interaction with a particular biological target. In particular, compounds according to the invention are disclosed as agonists or antagonists of a mammalian motilin receptor and a mammalian ghrelin receptor.

Spatially-defined macrocycles incorporating peptide bond surrogates

The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R, R, R, R, R, R, n, m, p Z, Z, and Zare as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.

Processes for intermediates for macrocyclic compounds

Novel spatially-defined macrocyclic compounds containing specific conformational control elements are disclosed. Libraries of these macrocycles are then used to select one or more macrocycle species that exhibit a specific interaction with a particular biological target. In particular, compounds according to the invention are disclosed as agonists or antagonists of a mammalian motilin receptor and a mammalian ghrelin receptor.

Spatially-defined macrocyclic compounds useful for drug discovery

Macrocyclic antagonists of the motilin receptor

Growing community of inventors

Québec, Canada

Éric Marsault